Invivo Anti-Mouse ICOSL (CD275) Recombinant mAb
Invivo Anti-Mouse ICOSL (CD275) Recombinant mAb
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | ICOSL (CD275) |
| Synonyms | ICOS ligand; B7 homolog 2 (B7-H2); B7-like protein Gl50; B7-related protein 1 (B7RP-1); LICOS; B7h; B7h2; B7rp1; Icosl; Icoslg |
| Location | Cell membrane |
| Accession | Q9JHJ8 |
| Clone Number | S-3749 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG2a,k |
| Application | FCM, in vivo ICOSL neutralization |
| Reactivity | Ms |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95% (Determined by SDS-PAGE) |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
ICOSL (CD275), also known as B7-H2, is a ~60 kDa transmembrane glycoprotein of the B7/immunoglobulin superfamily that delivers the key costimulatory signal to ICOS on activated T cells, thereby driving T-cell proliferation, Th1/Th2/Th17 cytokine secretion, germinal-center formation, plasma-cell differentiation and memory T-cell survival, while also undergoing reverse signaling into dendritic cells, B cells, endothelial cells or tumor cells to modulate adhesion, migration and cytokine output, and—uniquely in humans—additionally engaging CD28 and CTLA-4 to fine-tune both naïve and regulatory T-cell responses, positioning it as a central checkpoint in adaptive immunity, allergy, autoimmunity and cancer.
